No association between MTHFR A1298C and MTRR A66G polymorphisms, and MS in an Australian cohort

Journal of the Neurological Sciences

Volumn 252, Issue 1, 2007, Pages 49-52

  Szvetko, A L ^a   Fowdar, J ^a   Nelson, J ^a   Colson, N ^a   Tajouri, L ^a   Csurhes, P A ^b   Pender, M P ^b,c   Griffiths, L R ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Gene association; Homocysteine; MTHFR; MTRR; Multiple sclerosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); COBALAMIN; HOMOCYSTEINE; METHIONINE; METHIONINE SYNTHASE REDUCTASE;

AMINO ACID BLOOD LEVEL; ARTICLE; AUSTRALIA; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

AUSTRALIA; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; FERREDOXIN-NADP REDUCTASE; GENE FREQUENCY; GENOTYPE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC;

EID: 33845531860     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.10.006     Document Type: Article

References (23)

1. Levin L.I., Munger K.L., Ruberstone M.V., Peck C.A., Lennette E.T., Spiegelmen D., et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293 20 (2005) 2496-2500
2. Ebers G.C., Sadovnick A.D., and Risch N.J. A genetic basis for familial aggregation in multiple sclerosis. Nature 377 (1995) 150-151
3. Feix A., Winkelmayer W.C., Eberle C., Sunder-Plassmann G., and Fodinger M. Methionine synthase reductase MTRR 66A > G has no effect on total homocysteine, folate, and Vitamin B12 concentrations in renal transplant patients. Atherosclerosis 174 (2004) 43-48
4. Gaughan D.J., Kluijtmans L.A.J., Barbaux S., McMaster D., Young I.S., Yarnell J.W.G., et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 157 (2001) 451-456
5. Leclerc D., Wilson A., Dumas R., Gafuik C., Song D., Watkins D., et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci U S A 95 (1998) 3059-3064
6. Troen A.M. The central nervous system in animal models of hyperhomocysteinemia. Prog Neuro-Psychopharmacol Biol Psychiatry 29 7 (2005) 1140-1151
7. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 78 1 (1997) 523-526
8. van der Put N.M., Gabreels F., Stevens E.M., Smeitink J.A., Trijbels J.F., Eskes K.T., et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects. Am J Hum Genet 62 (1998) 1044-1051
9. Olteanu H., Munson T., and Banerjee R. Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry 41 (2002) 13378-13385
10. Kara I., Sazci A., Ergul E., Kaya G., and Kilic G. Association of the C677T and A1298C polymorphisms in the 5,10-methylenetetrahydrofolate reductase gene in patients with migraine risk. Mol Brain Res 111 (2003) 84-90
11. Keegan B.M., and Noseworthy J.H. Multiple Sclerosis. Annu Rev Med 53 (2002) 285-302
12. Lipton S.A., Kim W.K., Choi Y.B., Kumar S., D'Emilia D.M., Rayudu P.V., et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc Natl Acad Sci 94 (1997) 5923-5928
13. Chen Z., Ge B., Hudson T.J., and Rozen R. Microarray analysis of brain RNA in mice with methylenetetrahydrofolate reductase deficiency and hyperhomocysteinemia. Gene Expr Patterns 1 (2002) 89-93
14. Kruman C., Culmsee C., Chan S.L., Kruman Y., Guo Z., Penix L., et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20 (2000) 6920-6926
15. Fodinger M., Buchmayer H., and Sunder-Plassmann G. Molecular genetics of homocysteine metabolism. Miner Electrolyte Metab 25 (1999) 269-278
16. Muntjewerff J.W., Kahn R.S., Blom H.J., and den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 11 2 (2006) 143-149
17. Susser E., Brown A.S., Klonowski E., Allen R.H., and Lindenbaum J. Schizophrenia and impaired homocysteine metabolism: a possible association. Biol Psychiatry 44 2 (1998) 141-143
18. Lindenbaum J., Healton E.B., Savage D.G., Brust J.C., Garrett T.J., Podell E.R., et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. NEJM 318 26 (1988) 1720-1728
19. Ramsaransing G.S., Fokkema M.R., Teelken A., Arutjunyan A.V., Koch M., and De Keyser J. Plasma homocysteine levels in multiple sclerosis. J Neurol Neurosurg Psychiatry 77 2 (2006) 189-192
20. Baig S.M., and Ali Qureshi G. Homocysteine and vitamin B12 in multiple sclerosis. Biog Amines 11 (1995) 479-485
21. Vrethem M., Mattsson E., Hebelka H., Leerbeck K., Osterberg A., Landtblom A.M., et al. Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid. Mult Scler 9 3 (2003) 239-245
22. Besler H.T., and Comoglu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 6 3 (2003) 189-196
23. Ho P.I., Ortiz D., Rogers E., and Shea T.B. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 70 5 (2002) 694-702